FDA approves ripretinib as fourth-line treatment for GIST

The FDA has approved ripretinib tablets for the treatment of advanced gastrointestinal stromal tumor, or GIST, in the fourth-line setting.Ripretinib (Qinlock; Deciphera Pharmaceuticals, Inc.) is the first new drug specifically approved for fourth-line treatment of GIST. It was approved for use in adult patients who have been treated previously with three or more kinase inhibitor therapies, including imatinib, according to the FDA.The approval was based on data from the phase 3 INVICTUS study, which evaluated the impact of ripretinib compared with placebo on PFS among patients with advancedRead More

Share on facebook
Share on twitter
Share on linkedin